Studies have reported kidney stones during GLP-1 treatment, but they have not established that GLP-1 medicines directly cause stones. The Wegovy label reports more urinary tract stones in one cardiovascular trial, and a large study of people with diabetes also found an association. Other research looks at the chemistry of urine, which can offer clues about stone formation without showing how often people develop stones.
If you have new sharp pain in your side, back, lower abdomen or groin, blood in your urine, painful urination, or trouble passing urine, seek medical care right away. Fever or chills with possible stone symptoms or an inability to pass urine need urgent evaluation. A blockage with infection can be an emergency. NIDDK kidney stone symptoms and European Association of Urology guideline.
What have studies actually counted?
| Evidence | What researchers found | How to use it |
|---|---|---|
| Wegovy cardiovascular trial | The U.S. label reports urolithiasis in 1.2% with Wegovy and 0.8% with placebo. Urolithiasis includes stones anywhere in the urinary tract. | A product- and trial-specific result in adults with cardiovascular disease and overweight or obesity. It does not give a rate for other GLP-1 medicines. |
| Veterans Affairs medical-record study | Among people with diabetes, GLP-1 use was associated with more kidney stone diagnoses than usual care with other glucose-lowering medicines. | A clinical stone outcome, with possible differences between the people who received each kind of treatment. The study cannot pinpoint why diagnoses were more common. |
| 24-hour urine study in 44 adults with obesity and prior stones | During weight loss with GLP-1-based treatment, urinary oxalate fell. Measures of how readily common stone minerals could crystallize did not change significantly. | A finding about urine chemistry in people with prior stones. Researchers did not count new stone events. |
Sources: Wegovy prescribing information, section 6.1, VA cohort study, and Kidney360 urine study.
A person can have similar urine chemistry on two collection days and develop a stone later. A medical-record study can register a stone without explaining which conditions contributed to it. That is how a reassuring urine study and a signal in diagnoses can both be informative. They measure different things.
How does dehydration fit into this?
When you pass less urine, stone-forming substances can become more concentrated. Vomiting and diarrhea can also cause enough fluid loss to affect kidney function in the short term. The Wegovy and Zepbound labels warn about acute kidney injury due to volume depletion. That warning concerns a sudden decline in kidney function. It does not show that dehydration explains the stone findings.
If you have persistent nausea, vomiting or diarrhea on either medicine, contact your healthcare provider promptly. Seek assessment promptly if you cannot keep fluids down or are passing much less urine. For ordinary drinking routines between symptoms, see hydration on GLP-1. A fluid target for someone with recurring stones and a prescribed fluid restriction needs individual advice.
What should you bring up if you've already had a stone?
If you have the stone analysis or a prior 24-hour urine test, bring the results to your prescriber or urologist. Include when the stone occurred, whether it caused an infection or blockage, and whether you have a single working kidney or known kidney disease. Ask whether the existing prevention plan needs adjusting if appetite or fluid tolerance changes on treatment.
A 24-hour collection can help identify factors for future prevention. Imaging can help find a current stone or blockage. Blood tests address kidney function, and a urine sample can help check for blood or signs of infection. For example, if your kidney function was fine at a routine visit but you now have sharp pain and blood in your urine, that earlier test does not answer the new question. NIDDK kidney stone diagnosis guide.
Pain can come in waves, and vomiting may accompany it. Seek care right away for possible stone symptoms even if the pain briefly eases. If you are passing urine more often without those warning symptoms, see our guide to tirzepatide and frequent urination for the distinction between trips to the bathroom and total urine output.

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.


